0001209191-21-016099.txt : 20210302
0001209191-21-016099.hdr.sgml : 20210302
20210302164350
ACCESSION NUMBER: 0001209191-21-016099
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210226
FILED AS OF DATE: 20210302
DATE AS OF CHANGE: 20210302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rickard Jason
CENTRAL INDEX KEY: 0001808505
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34620
FILM NUMBER: 21704476
MAIL ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IRONWOOD PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001446847
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043404176
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 617-621-7722
MAIL ADDRESS:
STREET 1: 100 SUMMER STREET, SUITE 2300
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-26
0
0001446847
IRONWOOD PHARMACEUTICALS INC
IRWD
0001808505
Rickard Jason
C/O IRONWOOD PHARMACEUTICALS, INC.
100 SUMMER STREET, SUITE 2300
BOSTON
MA
02110
0
1
0
0
SVP, Chief Operating Officer
Class A Common Stock
2021-02-26
4
S
0
2668
9.11
D
317665
D
Class A Common Stock
2021-02-26
4
S
0
1627
9.11
D
316038
D
Class A Common Stock
2021-02-26
4
S
0
3197
9.11
D
312841
D
Class A Common Stock
2021-02-26
4
S
0
6159
9.11
D
306682
D
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February
27, 2017.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on February
21, 2018.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January
29, 2019.
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February 27, 2020.
/s/ Brian Tessler, Attorney-in-Fact
2021-03-02